Molecular basis of primary hyperoxaluria and strategies for diagnosis

Bibliography

• Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013;369:649-58
   PubMed Web of Science ®Google Scholar
• Zhang X, Roe SM, Pearl LH, Danpure CJ. Crystallization and preliminary crystallographic analysis of human alanine:glyoxylate aminotransferase and its polymorphic variants. Acta Crystallogr D Biol Crystallogr 2001;D57:1936-7
   Google Scholar
• Motley A, Lumb MJ, Oatey PB, et al. Mammalian alanine/glyoxylate aminotransferase 1 is imported into peroxisomes via the PTS1 translocation pathway. Increased degeneracy and context specificity of the mammalian PTS1 motif and implications for the peroxisome-to-mitochondrion mistargeting of AGT in primary hyperoxaluria type 1. J Cell Biol 1995;131:95-109
   PubMedGoogle Scholar
• Huber PAJ, Birdsey GM, Lumb MJ, et al. Peroxisomal import of human alanine:glyoxylate aminotransferase requires ancillary targeting information remote from its C-terminus. J Biol Chem 2005;280:27111-20
   PubMedGoogle Scholar
• Fodor K, Wolf J, Erdmann R, et al. Molecular requirements for peroxisomal targeting of alanine-glyoxylate aminotransferase as an essential determinant in primary hyperoxaluria type 1. PLoS Biol 2012;10:e1001309
   PubMedGoogle Scholar
• Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type 1. Biomed Res Int 2013;2013:687658
   PubMedGoogle Scholar
• Zhang X, Roe M, Hou Y, et al. Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. J Mol Biol 2003;331:643-52
   PubMed Web of Science ®Google Scholar
• Montioli R, Fargue S, Lewin J, et al. The N-terminal extension is essential for the formation of the active dimeric structure of liver peroxisomal alanine:glyoxylate aminotransferase. Int J Biochem Cell Biol 2012;44:536-46
   PubMed Web of Science ®Google Scholar
• Danpure CJ, Birdsey GM, Rumsby G, et al. Molecular characterization and clinical use of a polymorphic tandem repeat in an intron of the human alanine:glyoxylate aminotransferase gene. Hum Genet 1994;94:55-64
   PubMedGoogle Scholar
• Hopp K, Cogal AG, Bergstralh EJ, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 2015. [ Epub ahead of print]
   Google Scholar
• Purdue PE, Lumb MJ, Fox M, et al. Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991;10:34-42
   PubMedGoogle Scholar
• Kamoda N, Minatogawa Y, Nakamura M, et al. The organ distribution of human alanine-2-oxoglutarate aminotransferase and alanine-glyoxylate aminotransferase. Biochem Med 1980;23:25-34
   PubMedGoogle Scholar
• Rumsby G. Primary hyperoxaluria database. 2015. Available from: www.uclh.nhs.uk/phd [Accessed 20 February 2015]
   Google Scholar
• Purdue P, Lumb M, Allsop J, Danpure C. An intronic duplication in the alanine: glyoxylate aminotransferase gene facilitates identification of mutations in compound heterozygote patients with primary hyperoxaluria type 1. Hum Genet 1991;87:394-6
   PubMedGoogle Scholar
• Purdue PE, Takada Y, Danpure CJ. Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol 1990;111:2341-51
   PubMed Web of Science ®Google Scholar
• Tarn AC, von Schnakenburg C, Rumsby G. Primary hyperoxaluria type 1: diagnostic relevance of mutations and polymorphisms in the alanine:glyoxylate aminotransferase gene (AGXT). J Inherit Metab Dis 1997;20:689-96
   PubMedGoogle Scholar
• Amoroso A, Pirulli D, Florian F, et al. AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol 2001;12:2072-9
   PubMedGoogle Scholar
• Lumb MJ, Danpure CJ. Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease causing mutations. J Biol Chem 2000;275:36415-22
   PubMedGoogle Scholar
• Cellini B, Montioli R, Voltattorni CB. Human liver peroxisomal alanine:glyoxylate aminotransferase: Characterisation of the two allelic forms and their pathogenic variants. Biochim Biophys Acta 2011;1814:1577-84
   PubMedGoogle Scholar
• Tammachote R, Kingsuwannapong S, Scrichomthong C, et al. Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2. Am J Med Genet A 2012;158A:2124-30
   PubMedGoogle Scholar
• Williams EL, Kemper MJ, Rumsby G. A de novo mutation in the AGXT gene causing primary hyperoxaluria type 1. Am J Kidney Dis 2006;48:481-3
   PubMedGoogle Scholar
• Chevalier-Porst F, Rolland M-O, Cochat P, Bozon D. Maternal isodisomy of the telomeric end of chromosome 2 is responsible for a case of primary hyperoxaluria type 1. Am J Med Genet A 2005;132A:80-3
   PubMedGoogle Scholar
• Hoppe B, Danpure CJ, Rumsby G, et al. A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity. Am J Kidney Dis 1997;29:36-44
   PubMed Web of Science ®Google Scholar
• Coulter-Mackie MB, Lian Q, Wong SG. Overexpression of human alanine:glyoxylate aminotransferase in Escherichia coli: renaturation from guanidine-HCl and affinity for pyridoxal phosphate co-factor. Protein Expr Purif 2005;41:18-26
   PubMedGoogle Scholar
• Hopper ED, Pittman AMC, Fitzgerald MC, Tucker CL. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine-glyoxylate aminotransferase. J Biol Chem 2008;283:30493-502
   PubMed Web of Science ®Google Scholar
• Laga MD, Pittman AMC, Roncador A, et al. Allele-specific characterization of alanine:glyoxylate aminotransferase variants associated with primary hyperoxaluria. PLoS One 2014;9:e94338
   PubMedGoogle Scholar
• Rumsby G, Williams E, Coulter-Mackie MB. Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Kidney Int 2004;66:959-63
   PubMed Web of Science ®Google Scholar
• Monico CG, Rossetti S, Schwanz HA, et al. Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene based diagnosis. J Am Soc Nephrol 2007;18:1905-14
   PubMed Web of Science ®Google Scholar
• Lumb M, Birdsey G, Danpure C. Correction of an enzyme trafficking defect in hereditary kidney disease in vitro. Biochem J 2003;374:79-87
   PubMedGoogle Scholar
• Pey AL, Salido E, Sanchez-Ruiz JM. Role of low native state kinetic stability and interaction of partially unfolded states with molecular chaperones in the mitochondrial protein mistargeting associated with primary hyperoxaluria. Amino Acids 2011;41:1233-45
   PubMed Web of Science ®Google Scholar
• Santana A, Salido E, Torres A, Shapiro L. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci USA 2003;100:7277-82
   PubMed Web of Science ®Google Scholar
• Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in Primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem 2013;288:2475-84
   PubMed Web of Science ®Google Scholar
• Purdue P, Lumb M, Allsop J, et al. A glycine-to-glutamate substitution abolishes alanine:glyoxylate aminotransferase catalytic activity in a subset of patients with primary hyperoxaluria type 1. Genomics 1992;13:215-18
   PubMedGoogle Scholar
• Cellini B, Bertoldi M, Montioli R, et al. Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications. Biochem J 2007;408:39-50
   PubMed Web of Science ®Google Scholar
• Cellini B, Montioli R, Paiardini A, et al. Molecular insight into the synergism between the minor allele of human liver peroxisomal alanine:glyoxylate aminotransferase and the F152I mutation. J Biol Chem 2009;284:8349-58
   PubMed Web of Science ®Google Scholar
• Danpure CJ, Purdue PE, Fryer P, et al. Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation. Am J Hum Genet 1993;53:417-32
   PubMedGoogle Scholar
• Cellini B, Montioli R, Paiardini A, et al. Molecular defects of the glycine 41 variants of alanine:glyoxylate aminotransferase associated with primary hyperoxaluria type 1. Proc Natl Acad Sci USA 2010;107:2896-901
   PubMed Web of Science ®Google Scholar
• Coulter-Mackie MB, Lian Q. Consequences of missense mutations for dimerization and turnover of alanine:glyoxylate aminotransferase: study of a spectrum of mutations. Mol Genet Metab 2006;89:349-59
   PubMed Web of Science ®Google Scholar
• Fargue S, Rumsby G, Danpure CJ. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 2013;1832:1776-83
   PubMed Web of Science ®Google Scholar
• Monico CG, Olson JB, Milliner DS. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type 1 primary hyperoxaluria. Am J Nephrol 2005;25:183-8
   PubMed Web of Science ®Google Scholar
• Frishberg Y, Rinat C, Khatib I, et al. Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Am J Nephrol 2005;25:269-75
   PubMedGoogle Scholar
• Williams EL, Rumsby G. Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50% of patients with primary hyperoxaluria type 1. Clin Chem 2007;53:1216-21
   PubMed Web of Science ®Google Scholar
• Montioli R, Roncador A, Oppici E, et al. S81L and G170R mutations causing primary hyperoxaluria type 1 in homozygosis and heterozygosis: an example of positive interallelic complementation. Hum Mol Genet 2014;23:5998-6007
   PubMed Web of Science ®Google Scholar
• Williams H, Smith LJ. L-glyceric aciduria. A new genetic variant of primary hyperoxaluria. N Engl J Med 1968;278:233-9
   PubMed Web of Science ®Google Scholar
• Cramer SD, Ferree PM, Lin K, et al. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet 1999;8:2063-69
   PubMed Web of Science ®Google Scholar
• Rumsby G, Cregeen D. Identification and expression of a cDNA for human hydroxypyruvate/glyoxylate reductase. Biochim Biophys Acta 1999;1446:383-8
   PubMedGoogle Scholar
• Cregeen DP, Williams EL, Hulton SA, Rumsby G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 2003;22:497
   PubMed Web of Science ®Google Scholar
• Behnam JT, Williams EL, Brink S, et al. Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells. Biochem J 2006;394:409-16
   PubMed Web of Science ®Google Scholar
• Booth MPS, Conners R, Rumsby G, Brady RL. Structural basis of substrate specificity in human glyoxylate reductase/hydroxypyruvate reductase. J Mol Biol 2006;360:178-89
   PubMed Web of Science ®Google Scholar
• Mdluli K, Booth MPS, Brady RL, Rumsby G. A preliminary account of the properties of recombinant human glyoxylate reductase (GRHPR), LDHA and LDHB with glyoxylate and their potential roles in its metabolism. Biochim Biophys Acta 2005;1753:209-16
   PubMed Web of Science ®Google Scholar
• Webster K, Ferree P, Holmes R, Cramer S. Identification of missense, nonsense and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet 2000;107:176-85
   PubMedGoogle Scholar
• Fu Y, Rope R, Fargue S, et al. A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5’UTR causing primary hyperoxaluria type II. Clin Genet 2014. [Epub ahead of print]
   Google Scholar
• Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010;87(3):392-9
   PubMed Web of Science ®Google Scholar
• Riedel TJ, Knight J, Murray MS, et al. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 2012;1822:1544-52
   PubMed Web of Science ®Google Scholar
• Belostotsky R, Pitt J, Frishberg Y. Primary hyperoxaluria type III-a model for studying perturbations in glyoxylate metabolism. J Mol Med (Berl) 2012;90:1497-504
   PubMed Web of Science ®Google Scholar
• Riedel T, Johnson L, Knight J, et al. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS One 2011;6(10):e26021
   PubMedGoogle Scholar
• Williams EL, Bockenhauer D, Van’t Hoff WG, et al. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 2012;27:3191-5
   PubMed Web of Science ®Google Scholar
• Beck BB, Baasner A, Buescher A, et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 2013;21:162-72
   PubMedGoogle Scholar
• Clifford-Mobley O, Tims C, Rumsby G. The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria: a review of data from a referral centre. Ann Clin Biochem 2015;52:113-21
   PubMed Web of Science ®Google Scholar
• Barratt TM, Kasidas GP, Murdoch I, Rose GA. Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 1991;66:501-3
   PubMed Web of Science ®Google Scholar
• Williams EL, Bagg EAL, Mueller M, et al. Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing. Mol Genet Genomic Med 2015;3:69-78
   PubMedGoogle Scholar
• Nogueira PK, Vuong TS, Boutoon O, et al. Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1. Hum Mutat 2000;15:384-5
   PubMedGoogle Scholar
• Coulter-Mackie MB, Rumsby G, Applegarth DA, Toone JR. Three novel deletions in the alanine:glyoxylate aminotransferase gene of three patients with type 1 hyperoxaluria. Mol Genet Metab 2001;74:314-21
   PubMedGoogle Scholar
• Rumsby G. An overview of the role of genotyping in the diagnosis of the primary hyperoxalurias. Urol Res 2005;33:318-20
   PubMedGoogle Scholar
• Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012;27:1729-36
   PubMed Web of Science ®Google Scholar
• Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type 1 primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005;67:1704-9
   PubMed Web of Science ®Google Scholar
• Bergstralh EJ, Monico CG, Lieske JC, et al. Transplantation outcomes in Primary hyperoxaluria. Am J Transplant 2010;10:2493-501
   PubMed Web of Science ®Google Scholar
• Harambat J, van Stralen KJ, Espinosa L, et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 2012;7:458-65
   PubMed Web of Science ®Google Scholar
• Hatch M, Gjymishka A, Salido EC, et al. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011;300:G461-9
   PubMed Web of Science ®Google Scholar
• Hoppe B, Beck B, Gatter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006;70:1305-11
   PubMed Web of Science ®Google Scholar
• Hoppe B, Groothoff JW, Hulton SA, et al. Efficacy and safety of Oxalobacter formingenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011;26:3609-15
   PubMed Web of Science ®Google Scholar
• Jiang J, Salido EC, Guha C, et al. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation 2008;85:1253-60
   PubMedGoogle Scholar
• Guha C, Yamanouchi K, Jiang J, et al. Feasibility of hepatocyte transplantation-based therapies for Primary hyperoxalurias. Am J Nephrol 2005;25:161-70
   PubMedGoogle Scholar
• Salido E, Rodriguez-Pena M, Santana A, et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther 2011;19:870-5
   PubMed Web of Science ®Google Scholar
• Miyata N, Steffan J, Johnson ME, et al. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci USA 2014. [Epub ahead of print]
   Google Scholar
• Madoux F, Janovick JA, Smithson D, et al. Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening. Assay Drug Dev Technol 2015;13:16-24
   PubMed Web of Science ®Google Scholar
• Wallis Y, Payne S, McAnulty C, et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. 2013. Available from: http://www.acgs.uk.com/media/774853/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf
   Google Scholar
• Lench N, Barrett A, Fielding S, et al. The clinical implementation of non-invasive prenatal diagnosis for single-gene disorders: challenges and progress made. Prenat Diagn 2013;33:555-62
   PubMed Web of Science ®Google Scholar
• Frishberg Y, Zeharia A, Lyakhovetsky R, et al. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet 2014;51:526-9
   PubMed Web of Science ®Google Scholar
• Fernandes MX, Martin-Higueras C, Salido E. Searching for glycolate oxidase inhibitors in public chemical banks: leads for substrate reduction therapy in PH1. In Primary hyperoxaluria workshop; Chicago; 2014
   Google Scholar
• Pelkonen R, Kivirikko KI. Hydroxyprolinemia: an apparently harmless familial metabolic disorder. N Engl J Med 1970;283:451-6
   PubMed Web of Science ®Google Scholar
• Kumar P, Henikoff S, Ng P. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81
   PubMed Web of Science ®Google Scholar
• Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11:361-2
   PubMed Web of Science ®Google Scholar
• Lage MD, Pittman AMC, Roncador A, et al. Allele-specific characterization of alanine:glyoxylate aminotransferase variants associated with primary hyperoxaluria. PLoS One 2014;9:e94338
   PubMedGoogle Scholar